# ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation

> **NCT01972035** · PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 137 (actual)

## Conditions studied

- Transplantation Infection
- Epstein-Barr Virus Infections
- Cytomegalovirus Infections

## Interventions

- **DRUG:** Valacyclovir
- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT01972035
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-01
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972035, "ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01972035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*